The NCI and other groups have developed CARs targeting CD22 as an alternative antigen in BCP-ALL patients not responding to or relapsing after CD19-targeted strategies, particularly those with CD19− disease. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.